VF
PTGX icon

Virtu Financial’s Protagonist Therapeutics PTGX Stock Holding History

Virtu Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
+8,163
New +$853K 0.03% 314
2025
Q2 		– Sell
-4,140
Closed -$200K – 1936
2025
Q1 		$200K Buy
+4,140
New +$173K 0.01% 816
2021
Q1 		– Sell
-11,887
Closed -$240K – 1931
2020
Q4 		$240K Buy
+11,887
New +$256K 0.03% 761

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Virtu Financial's PTGX Position: Q2 2026 in Review

Virtu Financial opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 8,163 shares worth $1M. The stake represents 0.03% of the portfolio and ranks #314 among its holdings. This is a return to the name: Virtu Financial previously reported a position in PTGX as recently as Q1 2025.

Virtu Financial first reported a position in PTGX in Q4 2020 and has held it in 3 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Virtu Financial held 8,163 shares of Protagonist Therapeutics worth $1M as of Q2 2026.
  • Protagonist Therapeutics was a new Virtu Financial position in Q2 2026.
  • Protagonist Therapeutics made up 0.03% of Virtu Financial's portfolio in Q2 2026, its #314 holding.
  • Virtu Financial first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 3 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.